Literature DB >> 31756779

Ewing sarcoma with FEV gene rearrangements is a rare subset with predilection for extraskeletal locations and aggressive behavior.

Yusuke Tsuda1, Brendan C Dickson2, David Swanson2, Yun-Shao Sung1, Lei Zhang1, Paul Meyers3, John H Healey4, Cristina R Antonescu1.   

Abstract

The molecular hallmark of Ewing sarcoma (ES) is a fusion involving the EWSR1 gene and a member of the ETS family of transcription factors. EWSR1-FLI1 is the most common variant, occurring in 90% of cases, followed by EWSR1-ERG. In a small subset, the FUS gene can substitute for EWSR1 in these fusions. Only rare case reports have been described to date of ES with FEV gene rearrangements. In this study, we investigate the clinicopathologic and molecular features of 10 ES patients with FEV-rearrangements, either fused to EWSR1 (n = 4) or to FUS (n = 6). The median age at diagnosis was 38 years (range, 5-61 years); occurring in six males and four females. All tumors were located at extraskeletal sites, occurring more often in the axial soft tissues. Tumors had a similar morphologic appearance and immunophenotype as ES with more common EWSR1-ETS fusions. Of six patients with follow-up data, five patients (83%) developed metastasis and two patients (33%) died of their diseases. The diagnosis was confirmed either by fluorescence in situ hybridization and/or targeted RNA sequencing. In the five cases tested by targeted sequencing, the fusion transcripts were composed of EWSR1 or FUS fused to either exon 1 or 2 of FEV, retaining the FEV ETS DNA binding domain. This is the largest study to date investigating the ES subset with EWSR1/FUS-FEV fusions showing a predilection for extraskeletal sites and aggressive behavior.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990ETS; zzm321990EWSR1; zzm321990FEV; zzm321990FUS; Ewing sarcoma; gene fusions

Mesh:

Substances:

Year:  2019        PMID: 31756779      PMCID: PMC7135932          DOI: 10.1002/gcc.22828

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  32 in total

1.  The NFATc2 gene is involved in a novel cloned translocation in a Ewing sarcoma variant that couples its function in immunology to oncology.

Authors:  Károly Szuhai; Marije Ijszenga; Danielle de Jong; Apollon Karseladze; Hans J Tanke; Pancras C W Hogendoorn
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 2.  Round cell sarcomas beyond Ewing: emerging entities.

Authors:  Cristina Antonescu
Journal:  Histopathology       Date:  2013-11-12       Impact factor: 5.087

3.  Anchored multiplex PCR for targeted next-generation sequencing.

Authors:  Zongli Zheng; Matthew Liebers; Boryana Zhelyazkova; Yi Cao; Divya Panditi; Kerry D Lynch; Juxiang Chen; Hayley E Robinson; Hyo Sup Shim; Juliann Chmielecki; William Pao; Jeffrey A Engelman; A John Iafrate; Long Phi Le
Journal:  Nat Med       Date:  2014-11-10       Impact factor: 53.440

4.  BCOR-CCNB3 Fusion Positive Sarcomas: A Clinicopathologic and Molecular Analysis of 36 Cases With Comparison to Morphologic Spectrum and Clinical Behavior of Other Round Cell Sarcomas.

Authors:  Yu-Chien Kao; Adepitan A Owosho; Yun-Shao Sung; Lei Zhang; Yumi Fujisawa; Jen-Chieh Lee; Leonard Wexler; Pedram Argani; David Swanson; Brendan C Dickson; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2018-05       Impact factor: 6.394

5.  Characterization of the DNA binding and transcriptional activation domains of the erg protein.

Authors:  H R Siddique; V N Rao; L Lee; E S Reddy
Journal:  Oncogene       Date:  1993-07       Impact factor: 9.867

Review 6.  Soft tissue Ewing sarcoma--peripheral primitive neuroectodermal tumor with atypical clear cell pattern shows a new type of EWS-FEV fusion transcript.

Authors:  A Llombart-Bosch; A Pellín; C Carda; R Noguera; S Navarro; A Peydró-Olaya
Journal:  Diagn Mol Pathol       Date:  2000-09

7.  Analysis of the DNA-binding and transcriptional activation functions of human Fli-1 protein.

Authors:  V N Rao; T Ohno; D D Prasad; G Bhattacharya; E S Reddy
Journal:  Oncogene       Date:  1993-08       Impact factor: 9.867

8.  Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy.

Authors:  Y Kaneko; K Yoshida; M Handa; Y Toyoda; H Nishihira; Y Tanaka; Y Sasaki; S Ishida; F Higashino; K Fujinaga
Journal:  Genes Chromosomes Cancer       Date:  1996-02       Impact factor: 5.006

9.  Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.

Authors:  Massimo Milione; Patrizia Gasparini; Gabriella Sozzi; Vincenzo Mazzaferro; Andrea Ferrari; Paolo G Casali; Federica Perrone; Elena Tamborini; Alessio Pellegrinelli; Giorgio Gherardi; Gianluigi Arrigoni; Paola Collini; Adele Testi; Elena De Paoli; Antonella Aiello; Silvana Pilotti; Giuseppe Pelosi
Journal:  Histopathology       Date:  2014-02-25       Impact factor: 5.087

10.  Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV.

Authors:  Tony L Ng; Maureen J O'Sullivan; Catherine J Pallen; Malcolm Hayes; Paul W Clarkson; Mark Winstanley; Poul H B Sorensen; Torsten O Nielsen; Douglas E Horsman
Journal:  J Mol Diagn       Date:  2007-07-09       Impact factor: 5.568

View more
  3 in total

Review 1.  Latest developments in the pathobiology of Ewing sarcoma.

Authors:  Irina Karlina; Brett A Schroeder; Kirill Kirgizov; Olga Romantsova; Andrey L Istranov; Andrey Nedorubov; Peter Timashev; Ilya Ulasov
Journal:  J Bone Oncol       Date:  2022-07-01       Impact factor: 4.491

Review 2.  Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis.

Authors:  Dave N T Aryee; Valerie Fock; Utkarsh Kapoor; Branka Radic-Sarikas; Heinrich Kovar
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

Review 3.  Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.

Authors:  Neetha Nanoth Vellichirammal; Nagendra K Chaturvedi; Shantaram S Joshi; Donald W Coulter; Chittibabu Guda
Journal:  Cancer Lett       Date:  2020-11-25       Impact factor: 9.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.